News
IDIBELL and ICO researchers, awarded by the Children’s Tumor Foundation
The selected project is entitled “Targeting NF‐1 associated MPNST with aurora kinase inhibitors” and is awarded with the maximum compensation in their category, with $50,000. It is intended for the use of aurora kinase inhibitors to treat animal models generated in the ICO and IDIBELL premises.
The epidermal stem cells contribute to the development of squamous cell carcinoma
Researchers from the IDIBELL have led a study demonstrating that the expression of human papillomavirus oncoproteins in hair follicle (epidermal region where hair is regenerated) stem cells induces the development of skin carcinomas. These studies show that the origin of certain skin carcinomas resides in the altered function of stem cells. The skin squamous cell […]
La Vanguardia publishes an opinion article on research, by the IDIBELL general manager
The newspaper La Vanguardia publishes on Sunday, October 7th, an opinion article written by the IDIBELL general manager, Emilià Pola, on the future of the research and development in the world and in Catalonia. Pola highlights that “every biomedical researcher makes possible a business of 400,000 euros per year, five times more than it costs”. […]
Annual Report 2011
In 2011, IDIBELL have continued increasing its scientific output focused on improving the health of people. Our researchers have continued publishing in top international journals and participating in leading research projects. The annual report 2011 highlights the most important facts of the year at the centre. A new feature of this edition is the inclusion […]
IDIBELL leads a European project on developing strategies against liver disease
IT-LIVER is a 3.3-million Euros project funded by European Commission under its FP7 Marie Curie Actions. This project will be carried out by 8 academic-research institutions and 4 industrial partners from six European countries. The coordinator of IT-LIVER is Isabel Fabregat, head of the Biological clues of the invasive and metastatic phenotype group of the […]
The MED12 oncogene, key in response to cancer drugs
The MED12 oncogene is essential in monitoring response to new cancer drugs, according to the study published in Cell and leaded by researchers at the IDIBELL and ICO in collaboration with researchers from the Netherlands Cancer Institute (NKI) in Amsterdam. This research, published in Cell, has shown that MED12 oncogene plays a key role in […]
Animal models developed by researchers at IDIBELL and ICO can revolutionize the study of cancer
Some animal models developed by researchers at the Institute of Biomedical Research of Bellvitge (IDIBELL) and the Catalan Institute of Oncology (ICO) has served to validate the effectiveness of a new drug against ovarian cancer resistant to cisplatin. The multidisciplinary work, done in collaboration with the biopharmaceutical company Pharmamar, was published in the journal Clinical […]
Clément François: “We must promote music in children”
Last October 5th took place in the University of Barcelona (Bellvitge Campus) the conference “Musical practice for the development of speech segmentation abilities, behavioural and electrophysiological evidences”, by PhD. Clément François, researcher of the Institut de Neurosciences de la Méditerranée CNRS and Aux-Marseille Universities (France). The Cognition and Brain plasticity group, from the UB and […]